Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer
NCT06434090Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nanoliposomal irinotecan in colorectal cancer (CRC), sponsored by Sun Yat-sen University. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06434090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06434090.